Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medicare Part D Plans Expanding Five-Tier Formularies, Preferred Networks In 2013

This article was originally published in The Pink Sheet Daily

Executive Summary

A review of Part D plan design trends among the leading sponsors shows that Humana has switched to five-tier formularies, UnitedHealth is using a preferred pharmacy network and CVS Caremark is sponsoring plans that include community-based independents in its preferred network.

You may also be interested in...

Part D Trends For Five-Tier Formularies, Brand-Drug Coinsurance Rising, Analysis Finds

As Part D open enrollment kicked off Oct. 15, a Kaiser Family Foundation found almost 90% of national and near-national plans use five-tier formularies. And more plans are asking patients to shoulder a higher share of brand drug costs through coinsurance rather than a flat copay.

Preferred Pharmacy Networks Prevail In Part D Plans As Enrollment For 2014 Begins

The evolution of the Medicare Part D marketplace has made features that were virtually unknown at the start of the program into prominent parts of plan designs across the country, according to an analysis by the Kaiser Family Foundation.

Preferred Pharmacy Trend In Part D Attracts MedPAC’s Attention

The Medicare Payment Advisory Commission expressed concerns about the impact on access to medications that a growing trend for Medicare Part D plan sponsors to use preferred pharmacy networks might have, particularly in rural areas where a preferred pharmacy might be many miles away.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts